deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT03978520

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek)

A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: AbbVie

Conditions Systemic Lupus Erythematosus (SLE)
Interventions Elsubrutinib Placebo for elsubrutinib Placebo for upadacitinib Upadacitinib
Updated 28 times since 2019 Last updated: Jun 27, 2023 Started: Jul 25, 2019 Primary completion: Jan 19, 2022 Completion: Jul 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Systemic Lupus Erythematosus (SLE), this trial is completed. The trial is conducted by AbbVie and has accumulated 28 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

28 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2023 — Aug 2023 [monthly]

    Completed PHASE2

▶ Show 23 earlier versions

  1. Sep 2022 — Jan 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  10. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  11. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  12. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  13. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  14. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  15. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  16. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  17. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  18. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  19. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  20. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  21. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  22. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  23. Jul 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Amsterdam, Netherlands , Asahikawa-shi, Japan , Aurora, United States , Austin, United States , Aventura, United States , Barranquilla, Colombia , Beckley, United States , Beijing, China , Berlin, Germany and 134 more locations